newsfilter
← Latest News
GlobeNewswire·

Royalty Pharma Investor Day Highlights Strong Growth Outlook and Company's Plans to Drive Value Creation

On track to deliver Portfolio Receipts of $4.7 billion or more by 2030, significantly ahead of consensusGoal to achieve at least mid-teens average annual total shareholder return over next 5 years with significant upside